The Atopic dermatitis market Size was valued at USD 1.85 billion in 2021 and is projected to grow from USD 2.09 Billion in 2022 to USD 6.39 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 13.2% during the forecast period (2023 - 2032). Rising development of novel pipeline drugs, increasing demand for new biologics and product approvals, and growing number of atopic dermatitis industry are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
A global campaign to raise awareness about atopic dermatitis was launched by Leo Pharma in October 2022. The participants were four individuals with chronic skin diseases.
During January 2022, AbbVie Inc. revealed that the US FDA had given a nod to employ RINVOQ (upadacitinib) for treating severe atopic dermatitis in people over twelve years and adults. This is mainly for those who have not experienced any meaningful change after using either oral or intravenous drugs.
Arcutis Biotherapeutics refused their previously accepted roflumilast cream indicated for atopic dermatitis over age six on September thirteenth two thousand twenty-three. Zoryve, also known as the cream, is indicated for plaque psoriasis in America only.
The atopic dermatitis awareness campaign by Leo Pharma went live across the globe in October 2022. France, Italy, Germany, and Spain all had a total of four people suffering from chronic skin ailments.
On June twenty-sixth, 2022, Sanofi’s Dupixent (dupilumab) earned approval for moderate-severe AD in children aged six months up to five years old from the Food and Drug Administration (FDA).
Triventi Bio was able to get 92 million US dollars in financing through series A funding during the month of October 2023 to advance their main antibody program, called TRIV-509, through clinical development. The pre-clinical stage, which is where TRIV-509 currently is, will now be supported by that capital raised, and the company’s plans are expected to last until Phase IIa clinical trial phases.
On August twenty-fourth, 2021, AbbVie was granted approval by The European Commission, which is one of the strongest developing areas with Atopic Dermatitis cases on their claims against it; as the first JAK inhibitor in the EU market addressing moderate to severe form in the adult population including adolescents RINVOQ. Approval was based on Phase III programme data evaluating either RINVOQ monotherapy or combined with topical corticosteroids, which demonstrated rapid improvements in skin clearance and itch reduction.
A quick development of innovative pipeline medications is anticipated to propel the size of the atopic dermatitis market, which is anticipated to enjoy considerable expansion during the projected period. Additionally, the expansion of the atopic dermatitis sector and the rise in the need for novel biologics and product approvals are both expected to support the market's expansion.
The increasing incidence of atopic dermatitis and favorable reimbursement policies in developing nations are additional factors anticipated to fuel market expansion. Additionally, it is anticipated that increased government efforts to offer better and more economical care as well as increased knowledge of the disease's treatment options would have an impact on the worldwide market share for atopic dermatitis. Additionally, the quick development of technology, the increase in financing, and the expansion of government support for R&D are anticipated to open up a number of new opportunities that will have an influence on the development of the atopic dermatitis market throughout the course of the forecast period.
July 2023:Olumiant, a product of Eli Lilly and Incyte, was the first and only advanced systemic therapy to be authorized for adults with severe alopecia areata (AA) in June 2022. At one year after approval, opinions of the oral JAK are still favorable, and comparisons to the introduction of Dupixent in the treatment of atopic dermatitis (AD) show that these opinions are similar in terms of satisfaction, comfort, and perceived degree of advancement. However, the user bases and patient initiations of the brands vary. In fact, Olumiant's AD user base may have already started to plateau while Dupixent's patient initiations and AD user base both showed steady growth at a comparable post-launch time.
Rapid development of novel pipeline drugs to boost market growth
The rapid expansion of novel pipeline drugs is expected to boost the market growth in the projected period. Additionally, it is expected that the increased need for new biologics and product approvals will accelerate the market expansion of the atopic dermatitis. The increasing incidence of atopic dermatitis and favourable reimbursement policies in developing nations are additional factors anticipated to fuel market expansion. Additionally, the rise in public knowledge of the disease's treatments and numerous government attempts to offer better and more economical care are anticipated to have an impact on the market growth of the worldwide atopic dermatitis.
Companies are spending in R&D to create new products to compete in the lucrative market for atopic dermatitis. Major companies' revenue growth is anticipated to be helped in the upcoming years by the increasing number of pharmaceuticals that are advancing to the late stages of clinical trials after showing promising results. For instance, In April 2021, Galderma released phase 2b results for its investigational drug Nemolizumab in people with uncontrolled atopic dermatitis. In March 2021, Pfizer declared the experimental medicine abrocitinib to be non-inferior to the commercial drug Dupixent from Sanofi. Additionally, individuals with atopic dermatitis have an unmet demand for oral medications, which can be met by the introduction of the Janus kinase 1 (JAK1) inhibitor abrocitinib. The oral phase 2 medication Korsuva from Cara Therapeutics treats pruritus brought on by atopic dermatitis.
Additionally, it is projected that the emergence of biologics for the treatment of atopic dermatitis and an increase in product approvals will boost market expansion during the forecast period. For instance, The U.S. FDA authorised Dupixent (dupilumab) for use in children with atopic dermatitis between the ages of 6 months and 5 years old in June 2022. The U.S. FDA authorised RINVOQ (upadacitinib) for the treatment of severe atopic dermatitis in adults and children over the age of 12 in January 2022, according to a statement from AbbVie Inc. Patients who don't respond to their previous medication and injection treatments are advised to try RINVOQ.
Biologics are a relatively new category of medicine. One key element promoting the expansion of the biologics market is its focused strategy. Companies are making investments in the development of innovative biologics with great efficacy due to the high risk of disease recurrence. Dermatologists believe that biologics should be the first option for patients who have atopic dermatitis for a significant portion of the year despite the fact that they are not generally regarded as first-line treatments because of their enhanced efficacy, safety, and aimed approach to treating the disease.
The market segments of atopic dermatitis, based on type, includes Hormone, Erythropoietin, Monoclonal Antibodies, and Calcitonin. The Monoclonal Antibodies segment held the majority share in atopic dermatitis market revenue. The market is primarily driven by an increase in the prevalence of cancer, an increase in the demand for biosimilar monoclonal antibodies that are less expensive, a high demand for biologics, an increase in genomics R&D activities, and the introduction of technologically cutting-edge genetic platforms like next-generation sequencing.
The atopic dermatitis market segmentation, based on Application, includes Cancer, Blood Disorders, and Chronic Diseases. The Cancer dominated the market in 2021. This is due to the increasing prevalence of cancer, rising drug development, and growing research and development that anticipated to support the market during forecast period.
Figure 2: Atopic dermatitis market, by Application, 2021 & 2030 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The atopic dermatitis market data has been bifurcated by End User into Hospitals, Research Centers, and Clinics. The Hospitals segment dominated the market in 2021. The high incidence of atopic dermatitis, the increase in drug prices, the rising standard of living for lower and middle-class families, and the approval of new drugs. The expansion of the hospital segment is also anticipated, as more initiatives from various governmental agencies are being taken to enhance the infrastructure of hospitals.
February 2023:Pfizer Inc. announced that the United States (U.S.) Food and Drug Administration (FDA) approved its supplemental New Drug Application (sNDA) for CIBINQO® (abrocitinib), expanding its indication to include adolescents (12 to <18 years) with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. Prior to its approval, CIBINQO could only be used to treat adults who were at least 18 years old. This is a significant step forward for the many American teenagers who suffer with the chronic itching and pain caused by untreated moderate-to-severe atopic dermatitis.
August 2023:For increased efficacy, ARCTIVA products from Arctiva Wellness include the company's patented HYDROSURF glycolipid technology as well as FDA-approved active substances. Research and testing have shown that the fermented components in HYDROSURF reduce the surface tension of liquids, making them perfect for use in products that treat dry skin disorders including eczema, dermatitis, and even psoriasis flare-ups. The medicines, one designed for eczema and the other for psoriasis, both contain salicylic acid and colloidal oatmeal as active components to tackle typical symptoms of each ailment. A steroid-free formulation of synergistic substances was used in the ARCTIVA product line, which was introduced following a rigorous phase of research and development.  
Atopic Dermatitis Regional Insights
By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Atopic Dermatitis market is dominate the global market share. This is primarily due to an increase in atopic dermatitis prevalence, increased patient treatment awareness, and development in the atopic dermatitis sector. Additionally, a strong healthcare system and early acceptance of novel drugs. For instance, according to the 2022 National Eczema Association, there are around 16.5 million adults in the United States (7.3%) who have atopic dermatitis that first manifested at an early age, with nearly 40% suffering from moderate to severe condition.
Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: ATOPIC DERMATITIS MARKET SHARE BY REGION 2021 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe atopic dermatitis market is growing rate significant rate. In 2021, it is anticipated that the U.K. will constitute 20%-25% of the Western European market. Because of the high prevalence of atopic dermatitis among youngsters, improved awareness of atopic dermatitis, advantageous medical reimbursement rules, and well-established healthcare facilities that are expected to enhance U.K. market share, the region dominates the Western European market. Atopic eczema, the most prevalent type, affects 1 in 5 children & 1 in 10 adults in the UK, according to the National Eczema Society. The skin is frequently unbearably itchy, making the impulse to scratch difficult to ignore. When the condition flares up, the skin may also turn red, cracked, painful, and raw. Further, the Germany market of atopic dermatitis held the largest market share, and the UK market of atopic dermatitis was the fastest growing market in the European region
The Asia-Pacific Atopic Dermatitis Market is expected to grow at the fastest CAGR from 2022 to 2030. This is due the significant presence of quickly evolving healthcare technology, the large patient population, and the surge in healthcare spending. Moreover, China market of atopic dermatitis held the largest market share, and the India market of atopic dermatitis was the fastest growing market in the Asia-Pacific region
Atopic Dermatitis Key Market Players & Competitive Insights
Major market players are spending a lot of money on R&D to increase their product lines, which will help the market growth of atopic dermatitis even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the atopic dermatitis industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
One of the primary business strategies adopted by manufacturers in the global atopic dermatitis industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, atopic dermatitis industry has provided medicine & treatment with some of the most significant benefits. The atopic dermatitis market major player such as Sanofi S.A. (France), Pfizer Inc. (U.S), Astellas Pharma Inc. (Japan), and others are working to expand the market demand by investing in research and development activities.
In June 2022, Sanofi announced that the U.S. FDA has approved Dupixent (dupilumab) for use in children with atopic dermatitis between the ages of 6 months and 5 years and whose condition is not adequately controlled by topical prescription therapies or when those therapies are not recommended. The European Medicines Agency is reviewing a regulatory filing for this age range, and filings to regulatory authorities in other nations are also under progress.
Also, in March 2020, the US FDA approved Pfizer’s complementary new drug application (sNDA) for Eucrisa ointment, 2%, extending the lower age limit from 2 years down to 3 months in children with severe Atopic Dermatitis. The medication is a small, boron-based molecule with a low molecular weight, which facilitates easier skin penetration. In March 2020, the EMA also granted Staquis (crisaborole) approval for the treatment of mild to moderate atopic dermatitis in adults and children older than 2 years.
Key Companies in the market of atopic dermatitis includes
Atopic Dermatitis Industry Developments
June 2021:Amgen and Kyowa Kirin Co., Ltd. announced a partnership to jointly develop and market and sell KHK4083, that is Kyowa Kirin's potential first-in-class, Phase 3-ready anti-OX40 completely human monoclonal antibody in development of the treatment of atopic dermatitis, to potential in other autoimmune diseases. KHK4083 will be developed, produced, and marketed by Amgen under the conditions of the agreement for all markets from outside Japan, where Kyowa Kirin will retain full ownership.
March 2020:The FDA's approval of Eucrisa for use in children older than 3 years old has increased the drug's ability to generate income. Arcutis Biotherapeutics' roflumilast is a well-known PDE4 that is currently under development.
June 2022:A dermatology-based company, DERMALA Inc., has created cutting-edge, microbiome-based treatments for conditions like persistent skin disorders. The company has announced the issuance of Patent No. 11,364,214, entitled "COMPOSITIONS AND METHODS FOR TREATING ECZEMA." The intellectual property portfolio of DERMALA has grown with the addition of a fourth patent. The portfolio discusses leveraging the human microbiome to treat and prevent atopic dermatitis without the use of potentially harmful drugs or immunomodulators.
| Report Attribute/Metric | Details |
| Market Size 2021 | USD 1.85 billion |
| Market Size 2022 | USD 2.09 billion |
| Market Size 2030 | USD 6.39 billion |
| Compound Annual Growth Rate (CAGR) | 13.2% (2023-2032) |
| Base Year | 2021 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018 & 2020 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Application, End User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Sanofi S.A. (France), Pfizer Inc. (U.S), Astellas Pharma Inc. (Japan), and others |
| Key Market Opportunities | Rising development of novel pipeline drugs |
| Key Market Dynamics | Increasing demand for new biologics and product approvals |
Frequently Asked Questions (FAQ) :
The atopic dermatitis market size was valued at USD 1.85 Billion in 2021.
The global market is projected to grow at a CAGR of 13.2% during the forecast period, 2023-2032.
North America had the largest share in the global market
The key players in the market are Sanofi S.A. (France), Pfizer Inc. (U.S), Astellas Pharma Inc. (Japan), and others.
The Monoclonal Antibodies type category dominated the market in 2021.
The cancer application had the largest share in the global market.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
